The estimated Net Worth of Francesco Parlati is at least $2.11 Tisíc dollars as of 17 June 2019. Mr. Parlati owns over 6,246 units of Calithera Biosciences Inc stock worth over $2,110 and over the last 7 years he sold CALA stock worth over $0. In addition, he makes $0 as Vice President - Research at Calithera Biosciences Inc.
Francesco has made over 2 trades of the Calithera Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 6,246 units of CALA stock worth $16,489 on 17 June 2019.
The largest trade he's ever made was exercising 6,246 units of Calithera Biosciences Inc stock on 17 June 2019 worth over $16,489. On average, Francesco trades about 1,031 units every 44 days since 2018. As of 17 June 2019 he still owns at least 42,201 units of Calithera Biosciences Inc stock.
You can see the complete history of Mr. Parlati stock trades at the bottom of the page.
Dr. Francesco Parlati Ph.D. serves as Vice President - Research of the Company. Mr. Parlati joined Calithera in October 2012 and currently serves as our Vice President of Research. From 2011 to 2012, Mr. Parlati was Founder and Senior Director of Biology at Cleave Biosciences, a biotechnology company. Prior to that, Mr. Parlati held various scientific roles at California Institute of Technology, Proteolix Inc. and Rigel Pharmaceuticals, Inc. Mr. Parlati received a B.S. in Chemistry from Concordia University, a Ph.D. in Biology from McGill University and completed his postdoctoral fellowship at Memorial Sloan-Kettering.
Francesco Parlati is 51, he's been the Vice President - Research of Calithera Biosciences Inc since 2012. There are 12 older and 10 younger executives at Calithera Biosciences Inc. The oldest executive at Calithera Biosciences Inc is H. Ward Wolff, 71, who is the Independent Director.
Francesco's mailing address filed with the SEC is C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD. #200, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Calithera Biosciences Inc have traded over $23,150,153 worth of Calithera Biosciences Inc stock and bought 7,859,025 units worth $49,155,939 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Partners Gp, L.L.C.... a Deepika Pakianathan. On average, Calithera Biosciences Inc executives and independent directors trade stock every 43 days with the average trade being worth of $8,053. The most recent stock trade was executed by Deepika Pakianathan on 27 January 2023, trading 121,333 units of CALA stock currently worth $47,320.
calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells. tumor metabolism and tumor immunology are promising new interrelated fields for cancer drug discovery. recent clinical successes have demonstrated the potential to slow abnormal cell growth and create fundamentally new therapies for cancer patients. our investigational onco-metabolism medicines take advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. calithera’s discovery and development efforts are focused on solid tumors for which new treatments are urgently needed. we are currently developing our lead candidate in phase 2 trials in patients with renal cell carcinoma, triple negative breast cancer. targeting cancer, differently. our onco-metabolism approach brings an enhanced perspective to cancer.
Calithera Biosciences Inc executives and other stock owners filed with the SEC include: